Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.31-0.09 (-0.96%)
At close: 1:00PM EST
9.31 0.00 (0.00%)
After hours: 01:01PM EST
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma is down 9.90% to 9.74
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma reached an all time low at 9.61
  • T
    Tartiaboy
    I stated four months ago that I thought that LYEL was highly over valued for the stage of product development. I continue to believe that. IMO this is a $500-$1B company, not a $3B company.
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma reached an all time low at 10.20
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma is down 9.57% to 11.72
  • t
    tim
    The CEO was noted to take a medical lOA until early 2022. I was reading on EDGAR online that he has not completely resigned from the company. Any information as to the situation?
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma is up 9.04% to 15.26
  • M
    Mr. Buddah
    Cuz Buddah a straight pro since 1996 mentored by Sektor adtx
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma reached an all time low at 10.51
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma reached an all time low at 10.32
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma is up 8.83% to 14.23
  • f
    fatah
    What is going on here ?
  • J
    Joe
    WOW !!! This past weekend I read thru LYEL's entire website. What a pleasure...I was blown away. Here are just a couple of my observations from that read-thru. Although incorporated in 2018, this is a world-class company. Yahoo Finance reports they have 188 full-time employees. While reading the profiles of their executive management team and Board of Directors, several recognitions became readily visible and apparent to me. First, their leadership team and the company in general truly has "industry leaders" in their respective specialty areas-- scientific, operational, medical, financial management, corporate development, corporate funding, and overall corporate management and leadership, etc. etc. Not only leaders in their respective fields, but also in many or most cases, those leaders are also the key inventors and/or developers too. World class. Plus, they're extensively well connected and influential throughout the entire biotech industry, especially as it relates to cancers. Secondly, as I scanned the profiles, bios and photos of them, I also noticed something different and unusual. This leadership team seems to be about equally split 50/50between men and women, and also includes racial diversity. In my opinion, that's great to be balanced in those ways-- all exceptionally talented and superbly qualified for their positions. When reviewing their respective credentials -- in addition to their having excellent skills, backgrounds and passion for the science and cures they're developing -- I also gained a confidence level that this team seems unlikely to stumble in its product developments and roll-outs, given that they're so highly experienced and qualified. Next, I was highly impressed by the industry-leading product development "platforms" they've developed and employ to rapidly and effectively "screen" for their development programs. To me as a layman, these seem to be not just product-development "screening platforms"; they also provide proprietary and novel product development tools and capabilities for rapid and successful product development programs. These can enable then to have broad development efforts across many cancers, and can enable much more rapid, effective and efficient development progress than previously in the biotech field. Very innovative and proprietary. So those were my first impressions from reading their website. I highly recommend you review it too. All of what I say above is from my own perspective as a layman stock investor significantly invested in biotechs.
  • E
    Erik
    Big money causing share prices of TCR-T and ACT companies to drop...picking up shares on the cheap after seeing the writing on the wall for TCR-T therapy efficacy and likelihood of increasing number of FDA approvals.
  • T
    Tartiaboy
    I have over 40 years following biotech companies, with intensive investing for the last 20+ years. I cannot find a rational explanation for LYEL having a MC of close to $4B. I understand they have a new technology, but it's in very early development. Aside from backing by some big names, what justifies this MC?

    IMO. The market cap should be between $500M and $1B.

    Open to reasoned responses. TIA.
  • D
    Dude
    $lyel now worth $4B pre clinical and $sls t cell has a P3 6 months out?? Markets are weird when short sellers manipulate the share price!
  • N
    NFLXBull Forever
    Anyone knows why this is getting hammered today?
  • T
    Terminal Gravity
    $ERYP conversation
    Are we getting options? If so, a really good thing...

    Hyacinth Markets
    @63_hyacinth

    new option listings and three option delistings on August 25th
    $BGSF $BSN $CXDO $EDUT $EPIX $ERYP $FKWL $HBB $HFFG $IMCC $INVO $ISSC $ITOS $KXIN $LNSR $LYEL $NMTC $RKLB $SMRT $VEV $XGN $ZEST $AJAX $FWAA $VACQ
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma is down 5.27% to 15.82
  • Y
    Yahoo Finance Insights
    Lyell Immunopharma is down 6.95% to 13.78